Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Bruce G. Allen Investments LLC

Bruce G. Allen Investments LLC boosted its position in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 26.6% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 3,485 shares of the biopharmaceutical company’s stock after acquiring an additional 732 shares during the quarter. Bruce G. Allen Investments LLC’s holdings in Bristol-Myers Squibb were worth $189,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. acquired a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $4,499,000. Glenview Trust co grew its position in Bristol-Myers Squibb by 0.4% during the 3rd quarter. Glenview Trust co now owns 109,894 shares of the biopharmaceutical company’s stock worth $6,378,000 after purchasing an additional 447 shares during the period. Rathbones Group PLC raised its stake in shares of Bristol-Myers Squibb by 128.6% during the 3rd quarter. Rathbones Group PLC now owns 57,564 shares of the biopharmaceutical company’s stock valued at $3,341,000 after buying an additional 32,379 shares during the last quarter. V Square Quantitative Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 32.1% in the 3rd quarter. V Square Quantitative Management LLC now owns 17,018 shares of the biopharmaceutical company’s stock valued at $988,000 after buying an additional 4,140 shares during the period. Finally, Azimuth Capital Investment Management LLC boosted its stake in shares of Bristol-Myers Squibb by 1.0% in the third quarter. Azimuth Capital Investment Management LLC now owns 130,362 shares of the biopharmaceutical company’s stock worth $7,566,000 after buying an additional 1,240 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on BMY shares. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Barclays decreased their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Finally, StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $60.00.

Read Our Latest Stock Report on BMY

Bristol-Myers Squibb Price Performance

Shares of BMY traded up $0.23 during trading hours on Thursday, hitting $41.05. 18,638,801 shares of the stock were exchanged, compared to its average volume of 15,506,325. The stock’s 50-day moving average price is $43.73 and its two-hundred day moving average price is $48.50. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $66.38. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The company has a market cap of $83.20 billion, a price-to-earnings ratio of -13.24, a price-to-earnings-growth ratio of 13.82 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.05 earnings per share. Research analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.85%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.